Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Trial ID or NCT#
This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more effective than a placebo in preventing melanoma in individuals with many moles and abnormal moles.
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma
Contact us to find out if this trial is right for you.
Cancer Clinical Trials Office
View on ClinicalTrials.gov